Rafael Santana-Davila, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Amgen
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
    Relationship end date:
    05/01/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Catalyst Pharmaceuticals
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Genentech
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Mirati Therapeutics
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Aztra-Zeneca
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Beyond Spring Pharmaceuticals
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Isa Pharmaceuticals
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Date added:
    08/21/2023
    Date updated:
    10/18/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    ALX Oncology
    Date added:
    08/21/2023
    Date updated:
    10/18/2024

Pages

Return to Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs